Zacks Research Upgrades Takeda Pharmaceutical (NYSE:TAK) to Hold

Takeda Pharmaceutical (NYSE:TAK) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Several other analysts have also commented on TAK. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday, January 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Finally, Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They issued an “overweight” rating for the company. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

TAK stock traded down $0.47 during midday trading on Tuesday, hitting $17.75. 2,715,800 shares of the stock traded hands, compared to its average volume of 3,084,449. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. The stock’s fifty day simple moving average is $17.11 and its 200-day simple moving average is $15.42. The firm has a market cap of $56.48 billion, a P/E ratio of 73.96 and a beta of 0.01.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.40. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. The business had revenue of $6.75 billion for the quarter, compared to analyst estimates of $7.81 billion. On average, analysts expect that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

Several large investors have recently bought and sold shares of TAK. Valeo Financial Advisors LLC lifted its stake in Takeda Pharmaceutical by 6.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock worth $175,000 after purchasing an additional 632 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Takeda Pharmaceutical by 3.8% in the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock valued at $285,000 after purchasing an additional 713 shares during the last quarter. Private Trust Co. NA lifted its position in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after buying an additional 783 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Takeda Pharmaceutical by 5.3% during the third quarter. EverSource Wealth Advisors LLC now owns 16,927 shares of the company’s stock worth $248,000 after buying an additional 850 shares during the last quarter. Finally, Sanctuary Advisors LLC grew its holdings in Takeda Pharmaceutical by 4.0% in the 4th quarter. Sanctuary Advisors LLC now owns 23,626 shares of the company’s stock valued at $368,000 after buying an additional 912 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.